Biomea Fusion is a clinical-stage biopharmaceutical company focused on discovering and developing oral covalent small molecules to treat patients with metabolic diseases and genetically defined cancers.  Biomea Fusion's lead investigational compound, BMF-219, is a covalent menin inhibitor.  The company also develops BMF-500, a covalent FLT3 inhibitor.

Biomea Fusion

Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.

Biomea Fusion, Inc.

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Oct 16, 2024 4:13 AM	435da1fb
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Oct 16, 2024 4:13 AM	85902625
crunchbase trigger	general	Nov 27, 2024 12:50 PM	9c6ebf83
crunchbase profile	general
li profile	general
translate crunchbase fundingrounds	general
peers	general	Oct 16, 2024 4:13 AM	99d85446
news basic	general	Oct 16, 2024 4:13 AM	53135c50
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:BIOMEAFUSION

Biomea Fusion

Last Close

6.38

22/11 21:00

Market Cap

145.32M

Beta: -

Volume Today

490.54K

Avg: -